Our Mission
At DiveGenomics, our mission is to redefine the standard of care by transforming complex biological data into clear clinical pathways. We are dedicated to pioneering the "Digital Patient Twin"—a sophisticated AI-driven model that empowers clinicians to predict treatment efficacy and disease progression with unprecedented accuracy. By bridging the gap between advanced genomics and bedside medicine, we strive to ensure that every therapeutic decision is as unique as the patient’s own molecular signature.
Our Team
George Laliotis is a board-certified physician-scientist and innovator at the intersection of oncology, bioinformatics, and artificial intelligence. With a clinical background in Internal Medicine and advanced training from institutions including Johns Hopkins and Harvard Medical School, he has dedicated his career to bridging the gap between complex biological data and actionable clinical decisions. Prior to founding DiveGenomics, Dr. Laliotis held leadership roles at biotech, where he directed medical strategies for AI-enabled oncology innovation and led the design of precision medicine clinical trials. A recognized expert in the field, he is board-certified in AI in Medicine and has authored extensive research on genomic signatures and RNA regulation in solid tumors. At DiveGenomics, he combines his medical expertise with advanced data science to realize the next generation of personalized precision medicine.
George Laliotis, MD, MPH, MHA
Founder & Chief Executive Officer
